SCHEMBL531162

SCHEMBL531162

[CH]=CC=Cc1cccc2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXRA P19793 1/20 0.50
▸ CHAT P28329 5/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47
▸ MTNR1A P48039 1/20 0.46
▸ MTNR1B P49286 1/20 0.46
▸ PTGS1 P23219 1/20 0.45
▸ PTGS2 P35354 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.42
▸ CYP1A1 P04798 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ NPY1R P25929 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ NPY2R P49146 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ CYP1B1 Q16678 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916043 0.92 RXRA (0.47) RXRACHATHDAC8HDAC6MTNR1A
SCHEMBL4626591 0.87 RXRA (0.57) RXRACHATHDAC8HDAC6MTNR1A
SCHEMBL29399914 0.87 RXRA (0.57) RXRACHATHDAC8HDAC6MTNR1A
SCHEMBL4626594 0.87 RXRA (0.57) RXRACHATHDAC8HDAC6MTNR1A
SCHEMBL27495890 0.85 RXRA (0.55) RXRACHATHDAC8HDAC6MTNR1A
SCHEMBL27493524 0.85 RXRA (0.55) RXRACHATHDAC8HDAC6MTNR1A
SCHEMBL27525379 0.85 RXRA (0.55) RXRACHATHDAC8HDAC6MTNR1A
SCHEMBL10706694 0.82 CHAT (0.62) RXRACHATHDAC8HDAC6MTNR1A
SCHEMBL10706687 0.82 CHAT (0.62) RXRACHATHDAC8HDAC6MTNR1A
SCHEMBL10706700 0.82 CHAT (0.62) RXRACHATHDAC8HDAC6MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1610126-B1 A system for determining the electrical potential across a membrane UNIV CALIFORNIA (US) 2014-04-30 — — EP disclosed
EP-1409456-B1 DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS UNIV CALIFORNIA (US) 2012-02-08 — — EP disclosed
EP-0977035-B2 A system for determining the electrical potential across a membrane UNIV CALIFORNIA (US) 2010-07-21 — — EP disclosed
US-7687282-B2 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-03-30 — — US disclosed
US-7173130-B2 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-02-06 — — US disclosed
US-20070026384-A1 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-02-01 — — US disclosed
US-7118899-B2 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-10-10 — — US disclosed
US-7115401-B2 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-10-03 — — US disclosed
US-7087416-B2 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2006-08-08 — — US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 — — EP disclosed
US-20030129670-A1 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-07-10 — — US disclosed
US-20020164577-A1 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-11-07 — — US disclosed
US-20020137201-A1 DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-09-26 — — US disclosed
US-6342379-B1 Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-01-29 — — US disclosed
WO-2001042211-A2 DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-06-14 — — WO disclosed
US-6107066-A Detection of transmembrane potentials by optical methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-08-22 — — US disclosed
EP-0977035-A2 A system for determining the electrical potential across a membrane REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-02-02 — — EP disclosed
EP-0834074-B1 DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS UNIV CALIFORNIA (US) 1999-11-03 — — EP disclosed
EP-0834074-A1 DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-04-08 — — EP disclosed
WO-1996041166-A2 DETECTION OF TRANSMEMBRANE POTENTIALS BY OPTICAL METHODS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070026384-A1 Detection of transmembrane potentials by optical methods MBOAT1, TRPM4, NME4 RXRA 620/4885CHAT 2363/4885HDAC8 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback